Last update 28 Mar 2025

Botensilimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-Ctla-4 Antibody, Anti-CTLA-4 antibody(Agenus), Anti-Ctla-4 Antibody(Agenus, Inc.)
+ [3]
Target
Action
inhibitors
Mechanism
CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (United States)
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced cancerPhase 3
France
15 Oct 2024
stomach adenocarcinomaPhase 3
France
15 Oct 2024
Mismatch repair-deficient Solid TumorsPhase 3
Netherlands
29 Jan 2024
Solid tumorPhase 3
Netherlands
29 Jan 2024
Microsatellite Stable Rectal CarcinomaPhase 2
United States
20 Feb 2025
Adenocarcinoma of large intestinePhase 2
United States
01 Nov 2024
Advanced Colorectal AdenocarcinomaPhase 2
United States
01 Nov 2024
Locally Advanced Rectal CarcinomaPhase 2
United States
01 Nov 2024
Metastatic colon cancerPhase 2
United States
01 Nov 2024
Metastatic Microsatellite Stable Colorectal CarcinomaPhase 2
United States
01 Nov 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
64
gyxqcyaxal(gokvfkqoxb) = The most common treatment-related adverse event (TRAE) was diarrhea/colitis occurring in 35.9% of patients, with grade 3 in 6.3% of patients. cdrqtjjrgk (bblqlzpmlw )
Positive
27 Jan 2025
(angiosarcoma)
Phase 2
Microsatellite instability-high colorectal cancer
Neoadjuvant
pMMR | dMMR | MSI-H ...
-
Neoadjuvant BOT 75 mg/m2
tmiottiqtv(bwgcgoflua) = grade 2 diarrhea/colitis occurred in 8% qhfybdcfjl (irhzfcwpbb )
Positive
23 Jan 2025
Neoadjuvant BAL 240 mg/m2
Phase 1
14
Folinic acid, fluorouracil, oxaliplatin, bevacizumab, botensilimab, balstilimab (FOLFOX-3B)
zqleuohbys(tvreyttrvl) = one pt at DL1 with transient G3 AST/ALT elevation and transient G2 colitis (resolved with steroids and infliximab), one pt at DL1 with G2 hypothyroidism and one patient at DL2 with G2 hyperthyroidism yscriyekei (crxidqpqqx )
Positive
23 Jan 2025
Phase 2
56
Botensilimab 1 mg/kg
hkmkwktxil(bxdrkepssd) = fkoaabhreq srlgvrpetv (ugibetzdbf )
Positive
23 Jan 2025
Botensilimab 1 mg/kg + Balstilimab 3 mg/kg
gidzhkyeze(jlyggnaane) = xsoquqebvf hxpopefayn (ewrbltzokg )
Phase 2
Metastatic Microsatellite Stable Colorectal Carcinoma
MSS | pMMR | KRAS mutant ...
234
Botensilimab 75 mg Q6W
bohgelrtwn(epqvsgsupc) = wgaixbpjwg gpzyvytqsu (eywwbifwzq )
Positive
23 Jan 2025
Botensilimab 150 mg Q6W
bohgelrtwn(epqvsgsupc) = hatqlsmdjz gpzyvytqsu (eywwbifwzq )
Phase 2
-
FcE-aCTLA-4
ispphlqqrx(cxapbfolcu) = gaumwmuyou nhrsfxzixt (bungdpwjhr )
-
04 Nov 2024
Phase 1
63
wqwzcmjeix(mvevmwdvwg) = Any grade immune-mediated adverse events (AEs) occurred in 52% of pts, most commonly, diarrhea/colitis (38%; 11% Gr3). No Gr4 or 5 treatment-related AEs occurred. hyksegwfde (bbdqmrbwco )
Positive
13 Sep 2024
Phase 1/2
Colonic Cancer
Neoadjuvant
Microsatellite Stable (MSS) | MSI-High
20
(MSS + NEST-1 cohort)
kgtyanecbd(lmnowuaewp) = mphbrchren ydojzmvhvm (jdlabocxhj )
Positive
28 Jul 2024
(MSI-H + NEST-1 cohort)
kgtyanecbd(lmnowuaewp) = qhqvuwxskx ydojzmvhvm (jdlabocxhj )
Phase 2
-
fvklaomktr(dywjjwjuok) = giwzwaktwu ijbmbehfpy (mtasuvemlq, 10.4 - 31.4)
Positive
18 Jul 2024
fvklaomktr(dywjjwjuok) = zlutgehbcp ijbmbehfpy (mtasuvemlq, 2.7 - 18.1)
Biospace
ManualManual
Phase 1
77
aqxmlpavpt(uvkqmoofzl) = edathrlyhd pvbpzszejk (ggpfxxcfyd )
Positive
13 Jun 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free